8-KEarnings & ResultsExhibits & Filings

PFIZER INC 8-K Report, Financial Results (Oct 21, 2008)

Filed October 21, 2008For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on October 21, 2008, to report its financial results for the third quarter of 2008, as detailed in a press release attached as Exhibit 99. While the 8-K itself doesn't contain the specific financial figures, it serves as the official notification and filing mechanism for the market to access this crucial information. Investors should refer to the referenced press release for detailed performance metrics, including revenue, earnings, and any forward-looking statements or guidance provided by the company for the quarter ending September 30, 2008. The filing's primary purpose is regulatory compliance, ensuring timely disclosure of material financial information. The press release, incorporated by reference, would have contained the substance of Pfizer's performance during the third quarter. Therefore, understanding Pfizer's operational and financial standing as of that period requires a review of that specific press release, which is considered filed with the SEC through this 8-K.

Key Highlights

  • 1Pfizer Inc. (PFE) officially filed its Third Quarter 2008 financial results via an 8-K filing on October 21, 2008.
  • 2The key financial performance data for Q3 2008 is contained within a press release attached as Exhibit 99.
  • 3This 8-K filing serves as the formal notification to the market and the SEC about Pfizer's Q3 2008 financial outcomes.
  • 4Investors are directed to the referenced press release (Exhibit 99) for specific details on revenue, earnings, and other financial metrics.
  • 5The filing adheres to regulatory requirements for disclosing material financial information.
  • 6The event date for the financial results being reported is October 20, 2008.

Frequently Asked Questions

The actual financial numbers for Pfizer's third quarter of 2008 are located in the press release dated October 21, 2008, which is attached as Exhibit 99 to this 8-K filing. You will need to review that press release for specific details on revenue, earnings, and other financial performance indicators.

This 8-K filing is significant because it officially reports Pfizer's financial results for the third quarter of 2008. It ensures that this material information is publicly disclosed and filed with the SEC in a timely manner, allowing investors to assess the company's performance and make informed decisions.

This specific 8-K filing is primarily focused on the reporting of Q3 2008 financial results. Any strategic announcements, outlook, or forward-looking guidance would be detailed within the referenced press release (Exhibit 99). Investors should consult that document for such information.